Topic: antibody-drug conjugates
Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.
Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.
The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201.
AstraZeneca landed the PDUFA date for [fam-] trastuzumab deruxtecan after the FDA accepted its approval submission for priority review.
A week after Sarah Boyce exited Akcea, she's at the helm of Avidity Biosciences, a company aiming to take antibody-drug conjugates to the next level.
Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. With Merck’s Keytruda, the med shrank 71% of bladder tumors, new data show.
The project is built on the AlivaMab Mouse platform that is already widely used by in-house R&D teams at large biopharma companies.
After a bumper series of private funding rounds, cancer biotech ADC Therapeutics is now looking to go public with a $150 million NYSE IPO attempt.
The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.
ImmunoGen is set to layoff 220 employees to make its $240 million cash pile last past the delivery of phase 3 mirvetuximab data in 2022.